Unicycive Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)

3 Months Ended

Mar. 31, 2024

Schedule of Basic and Diluted Net Loss Per Share

The following table sets forth the computation of basic and diluted net loss per share of common and preferred stock (in thousands, except share and per share data):

	Three Months Ended March 31,
	2023			2024
Numerator:
Net loss	$	(14,575	)	$	(20,963	)
Less: Deemed dividends on Series A-1 Preferred Stock		(192	)		(208	)
Net loss attributable to common shares, basic and diluted		(14,767	)		(21,171	)

Denominator:
Weighted-average shares outstanding used in computing net loss per share attributable to common stockholders, basic and diluted		15,232,406			34,912,692
Net loss per share attributable to common stockholders, basic and diluted	$	(0.97	)	$	(0.61	)

Schedule of Outstanding Shares Potentially Dilutive Securities

The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive:

	Three Months Ended March 31,
	2023		2024

Options to purchase common stock		1,336,489		10,320,505
Warrants to purchase common stock		4,784,193		4,784,193
Contingently issuable warrants to purchase convertible preferred stock		157,000,888		160,958,167
Total		163,121,570		176,062,865